Screener
Ultragenyx Pharmaceutical RARE Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026.
- Filed
- May 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206960
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from maturities of marketable securities | 88 | 137 |
| Payments for intangible asset | (5) | (15) |
| Other | — | (1) |
| Net cash (used in) provided by investing activities | (49) | 120 |
| Effect of exchange rate changes on cash | (1) | 1 |
| Net decrease in cash, cash equivalents and restricted cash | (247) | (45) |
| Cash, cash equivalents and restricted cash at beginning of period | 436 | 184 |
| Cash, cash equivalents and restricted cash at end of period | $189 | $139 |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's investing cash flow?
- Ultragenyx Pharmaceutical (RARE) reported investing cash flow of -$49M in Q1 2026.
- How has Ultragenyx Pharmaceutical's investing cash flow changed year-over-year?
- Ultragenyx Pharmaceutical's investing cash flow decreased by 140.8% year-over-year, from $120M to -$49M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Ultragenyx Pharmaceutical's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude